An investigation on behalf of investors in NASDAQ:SGYP shares over potential wrongdoing at Synergy Pharmaceuticals Inc was announced and NASDAQ:SGYP stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 04/14/2017 -- An investigation on behalf of investors in shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) was announced over potential breaches of fiduciary duties by certain Synergy Pharmaceuticals director.
Investors who purchased shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Synergy Pharmaceuticals Inc officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
New York based Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. Synergy Pharmaceuticals Inc reported that its Net Loss increased from $117.50 million in 2015 to $198.61 million in 2016.
Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) declined from $6.73 per share in January 2017 to as low as $3.98 per share on April 6, 2017.
On April 13, 2017, NASDAQ:SGYP shares closed at $4.55 per share.
Those who purchased shares of Synergy Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com